Providers’ confidence was correlated with the availability of in-house genomic testing, more than 10 years of oncology experience, and high volumes of patients with lung cancer in general, and patients with EGFR-mutated and ALK-rearranged lung cancer. This evidence concerns the gene EGFR and lung cancer.